4D Molecular Therapeutics, Inc. (FDMT)
收市後：
| 前收市價 | 23.53 |
| 開市 | 23.45 |
| 買盤 | 23.18 x 200 |
| 賣出價 | 23.27 x 400 |
| 今日波幅 | 22.75 - 23.85 |
| 52 週波幅 | 9.44 - 36.25 |
| 成交量 | |
| 平均成交量 | 1,205,009 |
| 市值 | 1.189B |
| Beta 值 (5 年，每月) | 2.86 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.58 |
| 業績公佈日 | 2024年5月08日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 52.20 |
Zacks4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -13.24% and 100.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksStrength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Reuters
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy. The stock hit an over two-year high of $35.61 after the company released interim data on Saturday from the trial that tested the gene therapy, 4D-150, in patients with wet age-related macular degeneration (AMD), a leading cause of vision loss among older adults. Wet AMD is a long-lasting disorder that causes blurred vision or a blind spot in the central vision due to fluid or blood leaking into the macula.
